So far, such risk stratification has been performed not only for a selection of cardiac ion channelopathies, as already outlined in the Introduction section, but also for neuromuscular diseases with NaV1.4 variants [87], hearing loss related to KCNQ4 variants [88], and encephalopathies, including schizophrenia, with CACNA1I variants [89], and epilepsy with SCN1A [90], KCNB1 [91], HCN1 [92], KCNQ2 [93], and SCN2A [94] variants. This evidence concerns the gene SCN4A and Encephalopathy.